Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Free Cash Flow (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Free Cash Flow for 6 consecutive years, with -$10.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 117.02% to -$10.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$25.6 million, a 48.62% decrease, with the full-year FY2024 number at -$19.1 million, down 5.79% from a year prior.
  • Free Cash Flow was -$10.6 million for Q3 2025 at Inhibikase Therapeutics, down from -$5.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$2.0 million in Q3 2021 to a low of -$10.6 million in Q3 2025.
  • A 5-year average of -$4.7 million and a median of -$4.2 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 145828.38% in 2021, then skyrocketed 35.25% in 2024.
  • Inhibikase Therapeutics' Free Cash Flow stood at -$4.1 million in 2021, then rose by 13.17% to -$3.6 million in 2022, then grew by 3.2% to -$3.4 million in 2023, then tumbled by 55.28% to -$5.3 million in 2024, then tumbled by 98.16% to -$10.6 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Free Cash Flow are -$10.6 million (Q3 2025), -$5.6 million (Q2 2025), and -$4.1 million (Q1 2025).